A retrospective and prospective study of double malignancies in a tertiary care hospital in south India - a ten years’ experience

S. Carbin Joseph¹, C. Danny Darlington²*, G. Fatima Shirly Anitha³

¹Department of Surgery, Kanyakumari Government medical college, Kanyakumari District, Tamil Nadu, India
²Department of Urology, Stanley medical college, Chennai, Tamil nadu, India
³Department of Pediatrics, CSI Kalyani Hospital, Mylapore, Chennai, India

Received: 17 January 2016
Revised: 02 March 2016
Accepted: 17 March 2016

*Correspondence:
Dr. C. Danny Darlington,
E-mail: dannymbbs2009@yahoo.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: The occurrence of second malignancies in cancer survivors is not uncommon. Due to advances in diagnostic and therapeutic modalities, the survival of cancer patients has improved and the incidence of second malignancies is also on the rise. The second malignancy may be synchronous or metachronous. Though there are plenty of case reports on double malignancies, original studies are less. The present study aims to analyse the frequency, types of double malignancies and their effect on the morbidity and mortality of the patients.

Methods: This is a retrospective and prospective analysis of cancer patients done in a tertiary care hospital. All patients who presented with double malignancies from January 2004 to December 2014 were included. Retrospective data was obtained for cases from January 2004 to October 2011 and prospective data was obtained from November 2011 to December 2014. The study included 32 patients with double malignancies.

Results: Gynaecological malignancies were most common in our study, followed by head and neck and gastrointestinal malignancies. Most of the malignancies were synchronous (56.25%). Double malignancies involving the head and neck, female reproductive tract, breast can be explained by common etiological factors like Human papillomma virus (HPV). Field cancerisation explains the synchronous cancers in Head and neck, upper aero digestive tract and reproductive tract.

Conclusions: This study emphasises the importance of screening cancer patients for other primary malignancies during initial evaluation as well as during follow up period, in addition to the metastatic workup. It also stresses that timely reduction of risk factors in cancer survivors can prevent further malignancies.

Keywords: Double malignancies, Field cancerisation, HPV, Metachronous malignancy, Synchronous malignancy

INTRODUCTION

The war against cancer which started long back is still continued by the oncologists and radiotherapists. Despite the various modalities of treatments offered, the cure rates are not much gratifying. Although this is the situation regarding a single malignancy, now a days we encounter patients with double and triple malignancies. As a result of improvement in medical facilities and thereby the survival of cancer patients, the incidence of double malignancies is on the rise. The second cancers not only add to the morbidity and mortality of the patients but also to the distress of the treating surgeon and hence there is a need to study the nature of these double malignancies. The objective of this study was to estimate the frequency of double malignancies among all the malignancy cases studied, to analyze the common types of malignancies that occur together in relation to the
other systems of the body, to evaluate the effect of second malignancy on the morbidity and mortality of the patient, and to study the field effect in malignancies.

METHODS

This is a retrospective and prospective analysis of patients with malignancies done in a tertiary government medical college hospital involving the departments of general surgery, medical oncology, radiotherapy, and gynecology. All patients who presented with double malignancies from January 2004 to December 2014 (10 years) were included in the study. Retrospective data was obtained for cases from January 2004 to October 2011 and prospective data was obtained for patients who presented between November 2011 and December 2014. During the study period of ten years, we had a total of 23003 malignancy cases; out of which only 32 patients had double malignancies. All these 32 patients had accurate histopathological reports and were considered for the analysis. Some patients were followed up, while others lost follow up due to poor survival rates. Informed consent was obtained from all individual participants included in the study. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article. The study was approved by the institutions’ ethical committee.

Inclusion criteria

- Presence of at least two malignancies
- Histologically confirmed tumours
- Different histology in the two locations

Exclusion criteria

- Patients without proper histopathological reports and those in whom the second tumour was suspected to be metastasis from the first.

The selected patients were subjected to detailed clinical examination and were evaluated by biochemical, hematological investigations, FNAC (Fine Needle Aspiration Cytology), biopsy, imaging studies and endoscopy as needed. The interval of time to distinguish a metachronous from synchronous lesion was taken as six months.

RESULTS

In the present study, the youngest patient with double malignancies was 23 years and the oldest was 75 years of age. The mean age of all the patients with double malignancies studied was 48.21 years. 40.60% were males and 59.40% were females. One patient with advanced carcinoma stomach and carcinoma of the urinary bladder expired during the study period.

Figure 1: Gender distribution.

Figure 2: Synchronous versus metachronous malignancies.

Figure 3: First malignancies distribution.

Figure 4: Second malignancies distribution.
### Table 1: Details of the patients included in the study.

<table>
<thead>
<tr>
<th>Age Yrs</th>
<th>Gender</th>
<th>Cancer 1</th>
<th>Treatment</th>
<th>Cancer 2</th>
<th>Treatment</th>
<th>Interval</th>
<th>Other features</th>
</tr>
</thead>
<tbody>
<tr>
<td>45</td>
<td>Female</td>
<td>Cervix-Squamous cell carcinoma</td>
<td>Surgery</td>
<td>Ovary</td>
<td>Papillary serous adenocarcinoma</td>
<td>chemotherapy</td>
<td>Synchronous</td>
</tr>
<tr>
<td>29</td>
<td>Female</td>
<td>Cervix-Squamous cell carcinoma</td>
<td>Radiotherapy</td>
<td>Ovary adenocarcinoma</td>
<td>Surgery and chemotherapy</td>
<td>Metachronous, after 2 years</td>
<td>Post Radiotherapy, married for 12 years</td>
</tr>
<tr>
<td>48</td>
<td>Female</td>
<td>Cervix-Adeno carcinoma</td>
<td>Surgery</td>
<td>Ovary-mucinous adenocarcinoma</td>
<td>Surgery and chemotherapy</td>
<td>Synchronous</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Female</td>
<td>Cervix-Squamous cell carcinoma</td>
<td>surgery</td>
<td>Ovary- papillary cyst</td>
<td>adenocarcinoma</td>
<td>chemotherapy</td>
<td>Synchronous</td>
</tr>
<tr>
<td>32</td>
<td>Female</td>
<td>Cervix-Squamous cell carcinoma</td>
<td>Radiotherapy</td>
<td>Bilateral Breast</td>
<td>Infiltrating ductal</td>
<td>carcinoma</td>
<td>Synchronous</td>
</tr>
<tr>
<td>41</td>
<td>Female</td>
<td>Cervix-Squamous cell carcinoma</td>
<td>Surgery and Radiotherapy</td>
<td>Breast- Infiltrating ductal carcinoma</td>
<td>Surgery</td>
<td>Metachronous - 2 years</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Female</td>
<td>Cervix-Squamous cell carcinoma</td>
<td>Surgery</td>
<td>Labium major-Squamous cell carcinoma</td>
<td>Surgery</td>
<td>Synchronous</td>
<td></td>
</tr>
<tr>
<td>65</td>
<td>Female</td>
<td>Cervix-Squamous cell carcinoma</td>
<td>Radiotherapy</td>
<td>Rib-Chondrosarcoma</td>
<td>Surgery</td>
<td>Synchronous</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Female</td>
<td>Uterus-Gestational trophoblastic neoplasia</td>
<td>Surgery</td>
<td>Ovary- Endodermal sinus tumour + Dysgerminoma</td>
<td>Surgery and chemotherapy</td>
<td>Synchronous</td>
<td>Gravida 4, Live 1, Abortion 3, Married 3 years</td>
</tr>
<tr>
<td>45</td>
<td>Female</td>
<td>Uterus-leiomyxo sarcoma</td>
<td>surgery</td>
<td>Fallopian tube-Adenocarcinoma</td>
<td>Surgery and chemotherapy</td>
<td>Synchronous</td>
<td>Gravida 6, Married for 15 years</td>
</tr>
<tr>
<td>42</td>
<td>Female</td>
<td>Uterus Adeno-carcinoma</td>
<td>Surgery and Radiotherapy</td>
<td>Trachea-Adenocarcinoma</td>
<td>Chemotherap y</td>
<td>Metachronous - 3 years</td>
<td>Post radiation</td>
</tr>
<tr>
<td>28</td>
<td>Female</td>
<td>Uterus- Adeno carcinoma</td>
<td>Surgery</td>
<td>Bronchus-Adenocarcinoma</td>
<td>Chemotherap y</td>
<td>Metachronous - 3 years</td>
<td>Post Radiation</td>
</tr>
<tr>
<td>55</td>
<td>Female</td>
<td>Ovary-Papillary serous adeno carcinoma</td>
<td>Surgery, Chemotherap y</td>
<td>Breast- Infiltrating ductal carcinoma</td>
<td>Surgery</td>
<td>Synchronous</td>
<td>Gravida 6, Married for 37 years</td>
</tr>
<tr>
<td>70</td>
<td>Male</td>
<td>Tongue-Squamous cell carcinoma</td>
<td>Radiotherapy</td>
<td>Lip- Squamous cell carcinoma</td>
<td>Surgery</td>
<td>Synchronous</td>
<td>Tobacco chewer for 40 years</td>
</tr>
<tr>
<td>63</td>
<td>Male</td>
<td>Foot-Squamous cell carcinoma</td>
<td>Surgery- amputation</td>
<td>Oral cavity- Squamous cell carcinoma</td>
<td>Surgery</td>
<td>Metachronous - 10 years</td>
<td>Smoker -20 years</td>
</tr>
<tr>
<td>50</td>
<td>Male</td>
<td>Cheek-Squamous cell carcinoma</td>
<td>Radiotherapy</td>
<td>Esophagus Upper 1/3rd- Squamous cell carcinoma</td>
<td>Palliative surgery</td>
<td>Metachronous - 9 years</td>
<td>Smoker for 25 years, post Radiation</td>
</tr>
<tr>
<td>60</td>
<td>Male</td>
<td>Cheek-Squamous cell carcinoma</td>
<td>surgery</td>
<td>Lung- Squamous cell carcinoma</td>
<td>Radiotherapy</td>
<td>Synchronous</td>
<td>Smoker for 30 years</td>
</tr>
<tr>
<td>No.</td>
<td>Gender</td>
<td>Primary Diagnosis</td>
<td>Secondary Diagnosis</td>
<td>Treatment</td>
<td>Follow-up</td>
<td>Cause of Death</td>
<td>Notes</td>
</tr>
<tr>
<td>-----</td>
<td>--------</td>
<td>------------------</td>
<td>---------------------</td>
<td>----------</td>
<td>-----------</td>
<td>----------------</td>
<td>-------</td>
</tr>
<tr>
<td>49</td>
<td>Male</td>
<td>Cheek- Squamous cell carcinoma</td>
<td>Penis- Squamous cell carcinoma</td>
<td>Radiotherapy</td>
<td>Surgery</td>
<td>Synchronous-3 months</td>
<td>Tobacco chewer for 25 years, Post radiation</td>
</tr>
<tr>
<td>55</td>
<td>Female</td>
<td>Rectum- Adeno carcinoma</td>
<td>Cheek- Squamous cell carcinoma</td>
<td>Surgery and chemotherapy</td>
<td>Radiotherapy</td>
<td>Metachronous-8 months</td>
<td>Post chemotherapy</td>
</tr>
<tr>
<td>52</td>
<td>Female</td>
<td>Cheek- Squamous cell carcinoma</td>
<td>Thyroid- Follicular carcinoma</td>
<td>Radiotherapy</td>
<td>Surgery</td>
<td>Synchronous</td>
<td>Tobacco chewer for 20 years, post radiation</td>
</tr>
<tr>
<td>55</td>
<td>Male</td>
<td>Parotid- Adeno carcinoma</td>
<td>Back- soft tissue sarcoma</td>
<td>Surgery</td>
<td>Metachronous-2 years</td>
<td>Synchronous</td>
<td></td>
</tr>
<tr>
<td>63</td>
<td>Male</td>
<td>Supraglottis- Squamous cell carcinoma</td>
<td>Parotid- Adenocarcinoma</td>
<td>Radiotherapy</td>
<td>Inoperable-Palliation</td>
<td>Metachronous -7 years</td>
<td>Post radiation</td>
</tr>
<tr>
<td>40</td>
<td>Female</td>
<td>Colon- Adeno carcinoma</td>
<td>Esophagus- Squamous cell carcinoma</td>
<td>Surgery and chemotherapy</td>
<td>Surgery</td>
<td>Metachronous-2 years</td>
<td>Post chemotherapy</td>
</tr>
<tr>
<td>42</td>
<td>Male</td>
<td>Caecum-Adeno carcinoma</td>
<td>Stomach- Adenocarcinoma</td>
<td>Surgery and chemotherapy</td>
<td>Inoperable-Palliation</td>
<td>Metachronous -10 years</td>
<td>Smoker and alcoholic for 15 years, post chemotherapy</td>
</tr>
<tr>
<td>45</td>
<td>Female</td>
<td>Stomach- Adeno carcinoma</td>
<td>Urinary bladder- Transitional cell carcinoma</td>
<td>Advanced-inoperable</td>
<td>Expired</td>
<td>Synchronous</td>
<td>Tobacco chewer and smoker for 15 years</td>
</tr>
<tr>
<td>39</td>
<td>Male</td>
<td>Periampullary- Adeno carcinoma</td>
<td>Melanoma- nodular type</td>
<td>Advanced-inoperable</td>
<td>Palliative</td>
<td>Synchronous</td>
<td>Had cerebral metastases</td>
</tr>
<tr>
<td>75</td>
<td>Female</td>
<td>Fallopian tube- Adeno carcinoma</td>
<td>Small bowel -Non Hodgkins Lymphoma</td>
<td>Surgery and chemotherapy</td>
<td>Surgery and chemotherapy</td>
<td>Metachronous -3 years</td>
<td>Post chemotherapy</td>
</tr>
<tr>
<td>54</td>
<td>Male</td>
<td>Lung- Squamous cell carcinoma</td>
<td>Skull- Multiple myeloma</td>
<td>Radiotherapy</td>
<td>Chemotherap y</td>
<td>Synchronous</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Male</td>
<td>Kidney- Adeno carcinoma</td>
<td>Generalised nodal-Non Hodgkins lymphoma</td>
<td>Surgery (Radical Nephrectomy) Chemotherapy- y</td>
<td>Chemotherap y</td>
<td>Metachronous -10 years</td>
<td>Post chemotherapy</td>
</tr>
<tr>
<td>34</td>
<td>Male</td>
<td>Cervical nodes- Hodgkins Lymphoma</td>
<td>Esophagus upper 1/3rd- Squamous cell carcinoma</td>
<td>Radiotherapy</td>
<td>Palliative management</td>
<td>Metachronous -14 years</td>
<td>Post radiation</td>
</tr>
<tr>
<td>30</td>
<td>Male</td>
<td>Skin- Melanoma</td>
<td>Thigh- Squamous cell carcinoma</td>
<td>Advanced-only chemotherapy</td>
<td>Advanced-Palliative management</td>
<td>Synchronous</td>
<td>Known case of Oculocutaneous Albinism</td>
</tr>
<tr>
<td>23</td>
<td>Female</td>
<td>Inner canthus of eye-Basal cell carcinoma</td>
<td>Left eyelid- Squamous cell carcinoma</td>
<td>Surgery</td>
<td>Metachronous -3 years</td>
<td>Known case of Xeroderma Pigmentosum</td>
<td></td>
</tr>
</tbody>
</table>

Among the double malignancies, 56.25% were synchronous malignancies and 43.75% were metachronous. Metachronous malignancies occurred in the study population as early as eight months to as late as 14 years with a mean interval of 5.2 years between the two malignancies. Gynaecological malignancies were the most commonly observed malignancies in the study group. Gastrointestinal malignancies were the second most common followed by head and neck malignancies. Around 28.10% of malignancies occurred following radiotherapy and 12.50% occurred following chemotherapy.
DISCUSSION

The discussion about the cases in the present study can be simplified by classifying the cases into following groups:

- Gynaecological malignancies
- Head and Neck malignancies
- Gastro-intestinal malignancies
- Lymphoreticular malignancies
- Cutaneous malignancies

Gynaecological malignancies

Double malignancies of the female reproductive tract although rare, were the most common group observed in our study. According to one theory, the epithelia of cervix, uterus, fallopian tubes, ovaries and peritoneal surfaces simultaneously respond to a carcinogen. Shared hormonal receptors may also be responsible for the development of multiple primary malignancies in the female reproductive tract. The most common combination reported includes endometrial carcinoma and ovarian malignancies. Cervical malignancies coexisting with ovarian malignancies are very rare. Only two cases of squamous cell carcinoma of cervix and ovarian malignancies have been reported in literature. In our study there were four cases of co existent Squamous cell carcinoma of cervix and carcinoma ovary, which is a very rare finding (Table 1, Cases 1-4). In Case no. 2, the ovarian malignancy was metachronous occurring 2 years after radiotherapy. But in a report by Boice et al radiotherapy for carcinoma cervix was not found to increase the risk of secondary ovarian malignancies.

Cases no.5 and 6, represent two cases of squamous cell carcinoma of cervix with carcinoma breast. Lonardo D et al were the first to propose the relationship between human papilloma virus (HPV) and carcinoma breast. In another study conducted in Japan, HPV-16 genomes were identified in breast neoplastic tissues and axillary lymph nodes using PCR (polymerase chain reaction) method. Widschwendter et al identified HPV 16 genome in breast cancer patients with past history of carcinoma cervix. HPV associated carcinoma breast tends to occur at younger age groups, with sexual activity being a risk factor. Both the cases in the present study are of young age group (32 and 41 years). Thus the above two cases can be assumed as having HPV as the common etiological factor.

HPV has also been implicated in malignancies of oral cavity, vulva, vagina, rectum, melanoma, bladder. HPV 16, 31,33 are identified in vulvar malignant lesions. Thus HPV could be the shared etiological agent in Case no. 7, with synchronous carcinoma cervix and labium majora.

Chondrosarcoma has been reported to occur after radiotherapy for testicular malignancy. No case has been reported so far with synchronous carcinoma of the cervix and chondrosarcoma of the rib. Hence, Case no. 8, (Figure 5) is the first case reported of synchronous squamous cell carcinoma cervix and rib chondrosarcoma.

Cases no. 9, a 25 years old woman with three abortions, had synchronous uterine gestational trophoblastic neoplasm and ovarian endodermal sinus tumor with dysgerminoma. Case no.10, is a synchronous uterine leiomyosarcoma with fallopian tube adenocarcinoma. Case no. 11 and 12, are tracheobronchial adenocarcinomas presenting 3 years after treatment of uterine adenocarcinoma. All these four cases are extremely rare and have never been reported so far. Hence our study forms the first report of such cases of double malignancies.

Case no. 14, a case of synchronous papillary serous adenocarcinoma of ovary and infiltrating ductal carcinoma of breast, may be secondary to BRCA1/2 mutations. But synchronous carcinoma of the ovary and breast is very rare. Only two cases have been reported before.

Head and neck malignancies

Case no. 14, represents a chronic tobacco chewer, with synchronous carcinoma of posterior 1/3rd of tongue and the lower lip. Other than tobacco, HPV can be a factor in etiopathogenesis of both the malignancies as suggested by a study by Jain et al. Another possible explanation is the “field effect” which occurs in head and neck tumours and upper autodigestive tract. Case no. 15, metachronous carcinoma oral cavity 10 years after amputation for squamous cell carcinoma of the foot, could also be HPV induced. But no such double malignancy has been reported so far.

Case no. 16, was a patient, a chronic smoker, with synchronous carcinoma of cheek and squamous cell carcinoma of esophagus. This combination has been reported in multiple studies. The risk factors include alcoholism, smoking, male gender. Field cancerisation is a plausible explanation for this scenario.
Case no. 17, was a case of carcinoma cheek with synchronous squamous cell carcinoma of the lung. Lung malignancy with oral cavity secondary deposits and metachronous oral cavity carcinoma occurring after carcinoma lung has been reported. But synchronous cancers in these two locations have not been reported.  

Case no. 18, (Figure 6) presented with squamous cell carcinoma cheek, for which he received radiotherapy. After 3 months he presented again with a synchronous carcinoma of penis with bilateral inguinal nodal metastases. Such synchronous malignancies in these two organs have not been reported in literature. A probable role of HPV in the etiology of these two malignancies may be evident.

![Figure 6](image6.png)

**Figure 6:** (Case no. 18) - (a) Carcinoma Cheek which was treated with radiotherapy, (b) synchronous carcinoma of penis with bilateral inguinal secondaries in the same patient.

Case no. 19, is a woman with metachronous squamous cell carcinoma of the cheek occurring 8 months after surgery for adenocarcinoma of the rectum. This is the first instance in literature of such double malignancies.

![Figure 7](image7.png)

**Figure 7:** (Case no. 20) - Synchronous follicular carcinoma of thyroid, (a) and squamous cell carcinoma of the cheek (b) in a 52 year old woman.

Follicular carcinoma of the thyroid occurring synchronously with squamous cell carcinoma of the cheek (Case no. 20, Figure 7) parotid adenocarcinoma presenting synchronously with soft tissue sarcoma (Case no. 21) and metachronously 7 years after radiotherapy for supraglottic squamous cell carcinoma, with facial nerve paralysis (case no. 22, Figure 8), are the first ones to be reported.

![Figure 8](image8.png)

**Figure 8:** (Case no. 22) - Metachronous right parotid adenocarcinoma (with facial nerve palsy) seven years after radiotherapy for carcinoma supraglottis with left cervical node metastasis.

**Gastrointestinal malignancies**

Synchronous adenocarcinomas of the colon and the esophagus have been reported before. But metachronous squamous cell carcinoma of the esophagus with adenocarcinoma of colon has not been reported. Case no. 23, is a female with Squamous cell carcinoma of the esophagus presenting 2 years after successful treatment of adenocarcinoma of the colon. Studies linking these two malignancies point to alcoholism, smoking, dietary factors, cyclo-oxygenase 2 enzymes, Barret’s esophagus as the common etiological factors.

Gastric malignancy following colonic adenocarcinoma is rare and is usually seen in HNPCC (hereditary nonpolyposis colorectal cancer). Gastric malignancies are the second most common extra colonic malignancies in HNPCC following endometrial carcinomas. These malignancies present in young age (mostly between 40-48 years age) as is evident from our 42 year old patient (Case no. 24) who developed inoperable adenocarcinoma of the stomach 10 years following right hemicolectomy for carcinoma of the caecum.

Synchronous or metachronous carcinoma of the stomach and transitional cell carcinoma (TCC) of the urinary bladder are very rare, Only five cases have been reported in literature before. Case no. 25 in our study is probably the sixth reported case. The patient in our study is a 45 year old woman, a chronic tobacco user, who presented with synchronous advanced adenocarcinoma of the stomach and advanced TCC of the urinary bladder, and succumbed to the disease. As per Chaudhuri et al tobacco may be a common risk factor for both the malignancies in this patient.

Familial cases of synchronous pancreatic adenocarcinoma and malignant melanoma have been observed in the familial atypical multiple mole melanoma syndrome (FAMMM), due to mutations in the CDKN2A gene. Pancreatic malignancy in these patients occur at a younger age, associated with other malignancies.
report a 39 year old patient (Case no. 26), who presented with synchronous periampullary pancreatic adenocarcinoma and nodular melanoma with cerebral metastases and hemiplegia. There was no family history of melanoma or pancreatic malignancy.

**Lymphoreticular malignancies**

Case no. 27, is a 75 year old woman who presented with small bowel non-Hodgkin’s lymphoma (NHL), 3 years following surgery and chemotherapy (Cisplatin) for fallopian tube adenocarcinoma; and case no. 28, with synchronous squamous cell carcinoma of lung and multiple myeloma are the first cases to be reported. We also report the first case of NHL occurring 10 years after Radical nephrectomy for renal cell carcinoma (RCC). Case no. 29. Patients with NHL are at increased risk of RCC but not vice versa.39

But synchronous squamous cell carcinoma and pigmented malignant melanoma has not been reported in literature.31 The case no. 31, in the present study (Figure 9) is a known case of Oculocutaneous albinism, with synchronous melanoma of the right side of the neck and squamous cell carcinoma of the thigh. Both the lesions were advanced at presentation. Only palliative treatment was offered.

Xeroderma pigmentosa with both basal cell carcinoma and squamous cell carcinoma are rare with less than 10 such cases reported in literature.32,34 The case no. 32, in our study is a 23 years old female, a known case of Xeroderma pigmentosa, who presented with basal cell carcinoma of the inner canthus of left eye which was excised. Three years later she developed squamous cell carcinoma of the left lower eyelid (Figure 10).

**Figure 9:** (Case no. 30)- (a) Synchronous squamous cell carcinoma of the thigh (b) and malignant melanoma of right side of the neck (c) in a patient with Oculocutaneous albinism.

Carcinoma esophagus developing after radiotherapy for Hodgkin’s lymphoma is rare. It has been reported even 30 years following radiotherapy for Hodgkin’s lymphoma.30 The Case no. 30 developed squamous cell carcinoma 14 years after radiotherapy for Hodgkin’s lymphoma. The long duration and the absence of other risk factors point to prior radiation exposure as the etiology for esophageal malignancy.

**Cutaneous malignancies**

Only 27 cases of malignant melanoma have been reported in patients with Oculocutaneous Albinism.31 These patients develop amelanotic melanomas as they already have defective melanin pigmentation. Squamous cell carcinoma is also reported and it runs a more aggressive course, with high chance of recurrence in these patients.

The limitation of this study was, since the study includes retrospective cases, the patients could not be traced for gathering finer details. As the survival following second malignancy is poor, follow up was not adequate. Chemotherapy and Radiotherapy induced second primaries have a long latent period and a long term follow up could not be done. Hence the real incidence of second malignancies may be more. Pediatric malignancies were not included in the study. Advanced laboratory investigations and genetic studies were not done due to limited resources.

**CONCLUSION**

The frequency of double malignancies in our study was 1.5/1000. Double malignancies are most common in female reproductive tract, followed by head and neck malignancies. A predilection for younger age group was observed in gynaecological double malignancies and syndromic malignancies. Most double malignancies...
occur by chance alone. Synchronous malignancies in different organs carry worse prognosis than those that occur in the same organ, as the latter are resectable. Metachronous second malignancies occurring very late do not influence the outcome of the first cancer and the prognosis depends upon its stage at detection. Second malignancies have developed as late as 30 years after radiotherapy and this stresses the importance of regular surveillance in these patients. Whenever possible, preventive measures should be carried out against second malignancy in patients with cancers who are susceptible for multiple malignancies.

Funding: No funding sources
Conflict of interest: None declared

Ethical approval: The study was approved by the institutional ethics committee

REFERENCES


Cite this article as: Joseph SC, Darlington CD, Anitha GIF. A retrospective and prospective study of double malignancies in a tertiary care hospital in south India - a ten years’ experience. Int Surg J 2016;3:674-82.